<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380519</url>
  </required_header>
  <id_info>
    <org_study_id>CL04041078</org_study_id>
    <nct_id>NCT04380519</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</brief_title>
  <official_title>An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Pharm International, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Data Management 365</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>K-Research, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>R-Pharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to evaluate the efficacy and safety of a single dose&#xD;
      of RPH-104 (80 mg) or OKZ (64 mg) compared to placebo in addition to standard therapy in&#xD;
      patients with severe SARS-CoV-2 infection (COVID-19) at Day 15 of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of two phases:&#xD;
&#xD;
        -  Pilot phase: the first 189 patients were randomized in three groups to receive OKZ,&#xD;
           RPH-104 (63 patients per group), followed by an interim analysis of efficacy and safety&#xD;
           data.&#xD;
&#xD;
        -  The main phase was the conduct of all procedures prespecified in the protocol. Based on&#xD;
           results of interim analysis no changes were made regarding the sample size or primary&#xD;
           efficacy endpoint.&#xD;
&#xD;
      For each patient the study included the following periods:&#xD;
&#xD;
        -  Screening period for no more than 48 hours before the start of the day of randomization&#xD;
           (Day 1). During the screening period, an assessment was performed to determine whether&#xD;
           the patient met the eligibility criteria;&#xD;
&#xD;
        -  Treatment period lasting from the end of the screening (considered as the beginning of&#xD;
           the Day 1) to 23:59 of the Day 1, including randomization of the patients in the&#xD;
           treatment groups and then a single administration of the study drug;&#xD;
&#xD;
        -  Follow-up period lasting from 00:00 of the Day 2 to 23:59 of the Day 29, including an&#xD;
           assessment of the efficacy and safety after administration of the study drug.&#xD;
&#xD;
      Eligible patients were randomized to one of three treatment groups to receive a single&#xD;
      subcutaneous injection: RPH-104 80 mg, OKZ 64 mg or placebo in addition to standard care for&#xD;
      patients with COVID-19 as per the routine practice in participating facilities. Further,&#xD;
      during the term of hospitalization, the clinical observation was performed (Day 1 - Day 15 of&#xD;
      the Last Hospitalization Day (LHD), whichever comes first). This was followed by a follow-up&#xD;
      period from the from Day 15 or LHD (whichever comes first) to Day 29.&#xD;
&#xD;
      Standard COVID-19 therapy, as per the institution routine practice, was permitted during the&#xD;
      study, except the prohibited protocol medication (during the whole period of the study) and&#xD;
      tocilizumab and sarilumab (during the first 24 hours after the study treatment&#xD;
      administration).&#xD;
&#xD;
      In the absence of positive dynamics in the patient's condition (as per Investigator's&#xD;
      judgement), it was possible to administrate a single dose of tocilizumab or sarilumab (in&#xD;
      accordance with the actual recommendations), after the 24 hours from one of the study drug's&#xD;
      administration.&#xD;
&#xD;
      On Day 15 primary endpoint of patient's clinical status (response to the study therapy) was&#xD;
      assessed. The response to the therapy was considered as improvement of the patient's clinical&#xD;
      status by at least 1 point on a 6-point COVID-19 scale in the absence of tocilizumab or&#xD;
      sarilumab administration.&#xD;
&#xD;
      The last patient's visit in the study was the visit on Day 29. If the patient was discharged&#xD;
      from the hospital earlier than Day 15 or Day 29, patient's clinical status at these visits&#xD;
      were assessed by phone call.&#xD;
&#xD;
      The total expected duration of the study for each patient was not more than 31 days,&#xD;
      including 48 hours of screening, 1 day of the study drug administration and 28 days of&#xD;
      observation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2020</start_date>
  <completion_date type="Actual">July 24, 2020</completion_date>
  <primary_completion_date type="Actual">July 10, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Responders in Each Treatment Group</measure>
    <time_frame>Day 15</time_frame>
    <description>Proportion of patients, responded to the study therapy, in each of the treatment groups.&#xD;
A responder is a patient who has not received tocilizumab or sarilumab and who has a clinical status improvement of ≥1 point on the 6-point COVID-19 scale (where 1 is the most favorable outcome and 6 is the most undesirable outcome) 15 days after the administration of the study drug:&#xD;
Not hospitalized, no activity limitations.&#xD;
Not hospitalized, limited activity.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, supplemental oxygen with independent breathing.&#xD;
Hospitalized; mechanical ventilation (invasive/non-invasive) or Extracorporeal membrane oxygenation (ECMO).&#xD;
Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change Over Time in the Clinical Status of Patients Using a 6-point Ordinal Scale</measure>
    <time_frame>from Day 2 until Day 15, Day 29</time_frame>
    <description>Changes of patients' clinical status on a 6 points ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) over time.&#xD;
The 6-point ordinal scale included the following categories:&#xD;
Not hospitalized, no activity limitations.&#xD;
Not hospitalized, limited activity.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, supplemental oxygen, with independent breathing.&#xD;
Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO.&#xD;
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab</measure>
    <time_frame>Day 29</time_frame>
    <description>The proportion of patients with an improvement in clinical status by 2 or more points on the 6-point ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) during the study with no use of tocilizumab or sarilumab.&#xD;
The 6-point ordinal scale included the following categories:&#xD;
Not hospitalized, no activity limitations.&#xD;
Not hospitalized, limited activity.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, supplemental oxygen, with independent breathing.&#xD;
Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO.&#xD;
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study</measure>
    <time_frame>from Day 2 until the Day 29</time_frame>
    <description>The proportion of patients who received tocilizumab or sarilumab for COVID-19 during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate During the Study</measure>
    <time_frame>from Day 1 until Day 29</time_frame>
    <description>Mortality rate over the follow-up period of the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">372</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>RPH -104 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject randomized to receive subcutaneous single injection of 2 ml solution of RPH-104 on Day 1, in addition to standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olokizumab 64 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject randomized to receive subcutaneous single injection of 2 ml solution of Placebo on Day 1, in addition to standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPH-104 80 mg</intervention_name>
    <description>solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial</description>
    <arm_group_label>RPH -104 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olokizumab 64 mg</intervention_name>
    <description>solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)</description>
    <arm_group_label>Olokizumab 64 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. The presence of a voluntarily signed and dated Patient Informed Consent Form for&#xD;
             participation in this study, or a record of an Medical Consilium decision justifying&#xD;
             patient's participation in case of patient is unable to state his/her will.&#xD;
&#xD;
          2. Having either of the following COVID-associated respiratory syndromes:&#xD;
&#xD;
               -  pneumonia with oxygenation saturation SpO2 ≤93% (on room air) or respiratory rate&#xD;
                  greater than 30/min;&#xD;
&#xD;
               -  Acute respiratory distress syndrome (ARDS) ( PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤&#xD;
                  315 if PaO2 is not available).&#xD;
&#xD;
          3. COVID-19 diagnosis based on:&#xD;
&#xD;
               -  laboratory-confirmed SARS-CoV-2 infection as determined by Polymerase Chain&#xD;
                  Reaction method (PCR).&#xD;
&#xD;
        OR&#xD;
&#xD;
        • Bilateral changes in the lungs typical for COVID-19, based on chest computed tomography&#xD;
        results.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. A history of hypersensitivity to the study drugs (RPH-104 and/or OKZ), and/or their&#xD;
             components.&#xD;
&#xD;
          2. The presence of any of the following laboratory abnormalities:&#xD;
&#xD;
               -  absolute neutrophil counts &lt; 0.5 x 10^9 L&#xD;
&#xD;
               -  white blood cell count &lt; 2 x 10^9 L&#xD;
&#xD;
               -  platelet count &lt;50 x 10^9 L&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) ≥ 3.0 x&#xD;
                  Upper Limit of Normal (ULN)&#xD;
&#xD;
          3. Severe renal failure: creatinine clearance &lt; 30 mL/min&#xD;
&#xD;
          4. Septic shock (vasopressors are required to maintain mean arterial pressure ≥ 65 mm Hg&#xD;
             and lactate ≥ 2 mmol/L in the absence of hypovolemia)&#xD;
&#xD;
          5. The disease progresses to death over the next 24 hours, regardless of treatment,&#xD;
             according to Investigator.&#xD;
&#xD;
          6. Perforation of the gastrointestinal tract, a history of diverticulitis.&#xD;
&#xD;
          7. Administration of plasma from COVID-19 convalescent donors within 4 weeks before study&#xD;
             enrollment and/or planned administration during the study.&#xD;
&#xD;
          8. Recent (less then 5 half-lives) administration of tocilizumab or sarilumab;&#xD;
&#xD;
          9. Recent (less then 5 half-lives) or planned during the current study period use of the&#xD;
             following drugs:&#xD;
&#xD;
               -  biologics (except RPH-104 or OKZ) with immunosuppressive effect, including, but&#xD;
                  not limited to: Interleukin-1 (IL-1) inhibitors (anakinra, rilonacept,&#xD;
                  canakinumab), IL- 6 inhibitors (except tocilizumab and sarilumab), IL-17A&#xD;
                  inhibitors (secukinumab), tumor necrosis factor α (TNFα) inhibitors (infliximab,&#xD;
                  adalimumab, etanercept, etc.), antiB-cell drugs, etc.&#xD;
&#xD;
               -  other immunosuppressive drugs (with the exception of methotrexate in a dose of up&#xD;
                  to 25 mg/week), including, but not limited to:&#xD;
&#xD;
                    1. high doses of glucocorticoids (equivalent to prednisolone &gt; 1 mg/kg) orally&#xD;
                       or parenterally;&#xD;
&#xD;
                    2. Janus kinase (JAK) kinase inhibitors; cyclophosphamide, etc.&#xD;
&#xD;
         10. Concurrent participation in another clinical trial.&#xD;
&#xD;
         11. Pregnancy, breastfeeding.&#xD;
&#xD;
         12. A history of active tuberculosis, or active tuberculosis suspected by the&#xD;
             Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Samsonov</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer, R-Pharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private healthcare institution &quot;Clinical Hospital&quot; Russian Railways-Medicine named after N. A. Semashko&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>109386</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Healthcare Institution &quot;City Clinical Hospital № 15 named after O.M. Filatov&quot; of Moscow City Healthcare Department</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Federal Center for Cerebrovascular Pathology and Stroke&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University)</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Autonomous Education Institution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of the Russian Federation (Sechenov University)</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Central Clinical Hospital with Polyclinic&quot; of Administrative Directorate of the President of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution &quot;National Medicine Research Center on Cardiology&quot; By Ministry of Healthcare of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution of Healthcare &quot;City Clinical Hospital #52&quot;, Moscow City Healthcare Department</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State budgetary healthcare institution City Clinical Hospital named after S.I. Spasokukotsky Department of Health of the city of Moscow City Clinical Hospital No. 50</name>
      <address>
        <city>Moscow</city>
        <zip>127206</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Budget Institution of Healthcare &quot;Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>АО &quot;State Company &quot;Medsi&quot; based on Clinical Hospital №1&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>143442</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Volga Research Medical University&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603950</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budget Institution of Healthcare &quot;City Hospital №40&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Budgetary State Healthcare Institution &quot;National Medical Research Center named after B.A. Almazov&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budgetary Health Institution Voronezh Regional Clinical Hospital №1</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Healthcare Institution of Yaroslavl Region &quot;Yaroslavl Region Clinical Hospital of War Veterans&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <results_first_submitted>January 10, 2022</results_first_submitted>
  <results_first_submitted_qc>January 21, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">January 24, 2022</results_first_posted>
  <last_update_submitted>January 21, 2022</last_update_submitted>
  <last_update_submitted_qc>January 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2</keyword>
  <keyword>2019-nCoV</keyword>
  <keyword>2019 novel coronavirus</keyword>
  <keyword>Respiratory disease</keyword>
  <keyword>lung disease</keyword>
  <keyword>COVID-19</keyword>
  <keyword>coronavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT04380519/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted at 16 clinical sites in Russian Federation. 381 subjects were screened and 372 subjects were enrolled (randomized). A total of 371 subjects were treated, and 336 subjects completed the study. A total of 372 subjects were analyzed for efficacy in the Intent-to-Treat (ITT) Population, 352 subjects in the modified ITT Population (mITT) and 371 subjects were analyzed for safety in the Safety Population.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RPH -104 80 mg</title>
          <description>Subcutaneous single injection of RPH-104 80 mg (2 ml 40 mg/mL solution) on Day 1, in addition to standard therapy.</description>
        </group>
        <group group_id="P2">
          <title>Olokizumab 64 mg</title>
          <description>Subcutaneous single injection of Olokizumab 64 mg (0,4 ml 160 mg/mL solution) on Day 1, in addition to standard therapy.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Subcutaneous single injection of 2 ml solution of Placebo (Normal Saline) on Day 1, in addition to standard therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-Treat (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent-to-Treat (mITT)</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>relatives' decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RPH -104 80 mg</title>
          <description>Subcutaneous single injection of RPH-104 80 mg (2 ml 40 mg/mL solution) on Day 1, in addition to standard therapy.</description>
        </group>
        <group group_id="B2">
          <title>Olokizumab 64 mg</title>
          <description>Subcutaneous single injection of Olokizumab 64 mg (0,4 ml 160 mg/mL solution) on Day 1, in addition to standard therapy.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Subcutaneous single injection of 2 ml solution of Placebo (Normal Saline) on Day 1, in addition to standard therapy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="124"/>
            <count group_id="B3" value="124"/>
            <count group_id="B4" value="372"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" lower_limit="28.0" upper_limit="92.0"/>
                    <measurement group_id="B2" value="59.6" lower_limit="26.0" upper_limit="93.0"/>
                    <measurement group_id="B3" value="59.7" lower_limit="29.0" upper_limit="86.0"/>
                    <measurement group_id="B4" value="59.1" lower_limit="26.0" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Responders in Each Treatment Group</title>
        <description>Proportion of patients, responded to the study therapy, in each of the treatment groups.&#xD;
A responder is a patient who has not received tocilizumab or sarilumab and who has a clinical status improvement of ≥1 point on the 6-point COVID-19 scale (where 1 is the most favorable outcome and 6 is the most undesirable outcome) 15 days after the administration of the study drug:&#xD;
Not hospitalized, no activity limitations.&#xD;
Not hospitalized, limited activity.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, supplemental oxygen with independent breathing.&#xD;
Hospitalized; mechanical ventilation (invasive/non-invasive) or Extracorporeal membrane oxygenation (ECMO).&#xD;
Death.</description>
        <time_frame>Day 15</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>RPH -104 80 mg</title>
            <description>Subcutaneous single injection of RPH-104 80 mg (2 ml 40 mg/mL solution) on Day 1, in addition to standard therapy.</description>
          </group>
          <group group_id="O2">
            <title>Olokizumab 64 mg</title>
            <description>Subcutaneous single injection of Olokizumab 64 mg (0,4 ml 160 mg/mL solution) on Day 1, in addition to standard therapy.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous single injection of 2 ml solution of Placebo (Normal Saline) on Day 1, in addition to standard therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Responders in Each Treatment Group</title>
          <description>Proportion of patients, responded to the study therapy, in each of the treatment groups.&#xD;
A responder is a patient who has not received tocilizumab or sarilumab and who has a clinical status improvement of ≥1 point on the 6-point COVID-19 scale (where 1 is the most favorable outcome and 6 is the most undesirable outcome) 15 days after the administration of the study drug:&#xD;
Not hospitalized, no activity limitations.&#xD;
Not hospitalized, limited activity.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, supplemental oxygen with independent breathing.&#xD;
Hospitalized; mechanical ventilation (invasive/non-invasive) or Extracorporeal membrane oxygenation (ECMO).&#xD;
Death.</description>
          <population>The intent-to-treat (ITT) population included all randomized patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.434</p_value>
            <p_value_desc>Hochberg adjustment was applied for p-values</p_value_desc>
            <method>Maximal Likelihood Estimator (MLE) model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.012</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.880</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.073</p_value>
            <p_value_desc>Hochberg adjustment was applied for p-values</p_value_desc>
            <method>Maximal Likelihood Estimator (MLE) model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.125</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.989</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Over Time in the Clinical Status of Patients Using a 6-point Ordinal Scale</title>
        <description>Changes of patients' clinical status on a 6 points ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) over time.&#xD;
The 6-point ordinal scale included the following categories:&#xD;
Not hospitalized, no activity limitations.&#xD;
Not hospitalized, limited activity.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, supplemental oxygen, with independent breathing.&#xD;
Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO.&#xD;
Death.</description>
        <time_frame>from Day 2 until Day 15, Day 29</time_frame>
        <population>The ITT population was the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>RPH -104 80 mg</title>
            <description>Subcutaneous single injection of RPH-104 80 mg (2 ml 40 mg/mL solution) on Day 1, in addition to standard therapy.</description>
          </group>
          <group group_id="O2">
            <title>Olokizumab 64 mg</title>
            <description>Subcutaneous single injection of Olokizumab 64 mg (0,4 ml 160 mg/mL solution) on Day 1, in addition to standard therapy.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous single injection of 2 ml solution of Placebo (Normal Saline) on Day 1, in addition to standard therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Over Time in the Clinical Status of Patients Using a 6-point Ordinal Scale</title>
          <description>Changes of patients' clinical status on a 6 points ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) over time.&#xD;
The 6-point ordinal scale included the following categories:&#xD;
Not hospitalized, no activity limitations.&#xD;
Not hospitalized, limited activity.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, supplemental oxygen, with independent breathing.&#xD;
Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO.&#xD;
Death.</description>
          <population>The ITT population was the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <title>improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>worsening (including deaths)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>without change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no data</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <title>improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>worsening (including deaths)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>without change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no data</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab</title>
        <description>The proportion of patients with an improvement in clinical status by 2 or more points on the 6-point ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) during the study with no use of tocilizumab or sarilumab.&#xD;
The 6-point ordinal scale included the following categories:&#xD;
Not hospitalized, no activity limitations.&#xD;
Not hospitalized, limited activity.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, supplemental oxygen, with independent breathing.&#xD;
Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO.&#xD;
Death.</description>
        <time_frame>Day 29</time_frame>
        <population>The ITT population was the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>RPH -104 80 mg</title>
            <description>Subcutaneous single injection of RPH-104 80 mg (2 ml 40 mg/mL solution) on Day 1, in addition to standard therapy.</description>
          </group>
          <group group_id="O2">
            <title>Olokizumab 64 mg</title>
            <description>Subcutaneous single injection of Olokizumab 64 mg (0,4 ml 160 mg/mL solution) on Day 1, in addition to standard therapy.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous single injection of 2 ml solution of Placebo (Normal Saline) on Day 1, in addition to standard therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab</title>
          <description>The proportion of patients with an improvement in clinical status by 2 or more points on the 6-point ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) during the study with no use of tocilizumab or sarilumab.&#xD;
The 6-point ordinal scale included the following categories:&#xD;
Not hospitalized, no activity limitations.&#xD;
Not hospitalized, limited activity.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, supplemental oxygen, with independent breathing.&#xD;
Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO.&#xD;
Death.</description>
          <population>The ITT population was the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.393</p_value>
            <p_value_desc>unadjusted</p_value_desc>
            <method>Maximal Likelihood Estimator (MLE) model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.019</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.892</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.061</p_value>
            <p_value_desc>unadjusted</p_value_desc>
            <method>Maximal Likelihood Estimator (MLE) model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.098</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.975</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study</title>
        <description>The proportion of patients who received tocilizumab or sarilumab for COVID-19 during the study</description>
        <time_frame>from Day 2 until the Day 29</time_frame>
        <population>The ITT population was the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>RPH -104 80 mg</title>
            <description>Subcutaneous single injection of RPH-104 80 mg (2 ml 40 mg/mL solution) on Day 1, in addition to standard therapy.</description>
          </group>
          <group group_id="O2">
            <title>Olokizumab 64 mg</title>
            <description>Subcutaneous single injection of Olokizumab 64 mg (0,4 ml 160 mg/mL solution) on Day 1, in addition to standard therapy.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous single injection of 2 ml solution of Placebo (Normal Saline) on Day 1, in addition to standard therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study</title>
          <description>The proportion of patients who received tocilizumab or sarilumab for COVID-19 during the study</description>
          <population>The ITT population was the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Rate During the Study</title>
        <description>Mortality rate over the follow-up period of the study</description>
        <time_frame>from Day 1 until Day 29</time_frame>
        <population>The safety population included all patients who received the IP (371 patients: 124 patients in the OKZ group, 123/124 (99.2%) patients in the RPH-104 group (1 patient did not received the IP) and 124 patients in the Placebo group).</population>
        <group_list>
          <group group_id="O1">
            <title>RPH -104 80 mg</title>
            <description>Subcutaneous single injection of RPH-104 80 mg (2 ml 40 mg/mL solution) on Day 1, in addition to standard therapy.</description>
          </group>
          <group group_id="O2">
            <title>Olokizumab 64 mg</title>
            <description>Subcutaneous single injection of Olokizumab 64 mg (0,4 ml 160 mg/mL solution) on Day 1, in addition to standard therapy.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous single injection of 2 ml solution of Placebo (Normal Saline) on Day 1, in addition to standard therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Rate During the Study</title>
          <description>Mortality rate over the follow-up period of the study</description>
          <population>The safety population included all patients who received the IP (371 patients: 124 patients in the OKZ group, 123/124 (99.2%) patients in the RPH-104 group (1 patient did not received the IP) and 124 patients in the Placebo group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>5.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>6.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>4.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AEs), except serious ones, were recorded from the moment of the use of the IP. AEs recorded prior to the start of the study therapy, but after the patient was included in the study, were recorded in the electronic CRF Case report form (eCRF) as &quot;Concomitant diseases&quot;. AEs were registered until the end of the follow-up period (day 29).</time_frame>
      <desc>All AE analyses were performed in the safety population. (The safety population included all patients who received the IP.) No statistical comparisons were conducted on the AE data. Data for treatment-emergent AEs (TEAEs) were reported below. TEAE is an AE that started at or after the time of administration of the randomized IP.</desc>
      <group_list>
        <group group_id="E1">
          <title>RPH -104 80 mg</title>
          <description>Subject randomized to receive subcutaneous single injection of 2 ml solution of RPH-104 on Day 1, in addition to standard therapy&#xD;
RPH-104 80 mg: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial</description>
        </group>
        <group group_id="E2">
          <title>Olokizumab 64 mg</title>
          <description>Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy&#xD;
Olokizumab 64 mg: solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Subject randomized to receive subcutaneous single injection of 2 ml solution of Placebo on Day 1, in addition to standard therapy&#xD;
Placebo: Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Viral sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Cerebral ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="124"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="123"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="124"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any study related information could be made public available only after Sponsors written permission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sergey Grishin, Head of Scientific Affairs Department</name_or_title>
      <organization>R-Pharm</organization>
      <phone>0074959567937 ext 1506</phone>
      <email>sa.grishin@rpharm.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

